NMT Medical StarFlex Headache Prevention Study Ahead Of Schedule
This article was originally published in The Gray Sheet
Executive Summary
NMT Medical expects to complete patient enrollment for its MIST trial, evaluating the firm's StarFlex septal repair device's ability to prevent migraine headaches, in Q3 2005, President & CEO John Ahern stated in a recent investor call
You may also be interested in...
NMT Set To Study Next-Generation BioStar Tissue-Based PFO Closure Device
NMT Medical plans to begin human clinical studies of its next-generation, bio-resorbable patent foramen ovale (PFO) closure device,BioStar, in the second quarter of this year
NMT Set To Study Next-Generation BioStar Tissue-Based PFO Closure Device
NMT Medical plans to begin human clinical studies of its next-generation, bio-resorbable patent foramen ovale (PFO) closure device,BioStar, in the second quarter of this year
St. Jude PFO Program For Stroke, Migraine Gets Boost With Velocimed Deal
St. Jude Medical will accelerate its patent foramen ovale (PFO) R&D program for stroke treatment by acquiring Velocimed for more than $82.5 mil. under a definitive agreement, the firms said Feb. 15